7-bromo-6-hydroxy-2,2,5,8-tetramethylchroman | 26363-98-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并吡喃
• 英文名称: 7-bromo-6-hydroxy-2,2,5,8-tetramethylchroman
• 英文别名: 7-bromo-2,2,5,8-tetramethyl-chroman-6-ol；7-Bromo-2,2,5,8-tetramethyl-3,4-dihydrochromen-6-ol
• CAS: 26363-98-4
• 化学式: C₁₃H₁₇BrO₂
• 分子量: 285.181
• InChiKey: OMYWTIRBYKBGDI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4
• 重原子数：
  16
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.54
• 拓扑面积：
  29.5
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  6-hydroxy-2,2,5,8-tetramethylchroman 在 溴 作用下， 以 正己烷 为溶剂， 以82%的产率得到7-bromo-6-hydroxy-2,2,5,8-tetramethylchroman
  参考文献：
  名称：

  非α-生育酚的溴化：比较合成、动力学和计算研究

  摘要：

  广泛研究了三种非 α-生育酚及其截短的模型化合物在非极性溶剂中的溴化化学，并与 α-同类物的溴化化学进行了比较。溴化发生在所有非α-生育酚的游离芳香位置。在 δ-生育酚的情况下，C-5 优先于 C-7。在 5-甲基取代基的存在下，如在 β-生育酚中，通过氧化/加成机制通过相应的邻醌甲基化物形成 5a-溴衍生物成为一个竞争过程。通过测量不同温度下的产物比率，建立了平行反应（β-和δ-生育酚）的反应体系的相对活化能和绝对活化能。动力学数据与 DFT 结果非常吻合，DFT 结果表明 δ-生育酚溴化的产物比率与阳离子溴化中间体的稳定性相关。所有产品都经过全面表征，提供可靠的分析标准和参考化合物。(© Wiley-VCH Verlag GmbH & Co. KGaA, 69451 Weinheim, Germany, 2009)

  DOI：

  10.1002/ejoc.200900495

文献信息

• Treatment of mitochondrial diseases
  申请人：Walkinshaw Gail

  公开号：US20050065099A1

  公开（公告）日：2005-03-24

  The invention relates the method of treatment or amelioration of mitochondrial disorders such as Alzheimer's disease, Parkinson's disease, Friedreich's ataxia (FRDA), cerebellar ataxias, Leber's hereditary optic neuropathy (LHON), mitochondrial myopathy, encephalopathy, lactacidosis, stroke (MELAS), Myoclonic Epilepsy with Ragged Red Fibers (MERFF), amyotrophic lateral sclerosis (ALS), motor neuron diseases, Huntington's disease, macular degeneration, and epilepsy, with chroman derivatives of Formula I or Formula II as described herein.

  这项发明涉及治疗或改善线粒体疾病，如阿尔茨海默病、帕金森病、弗里德雷希共济失调症（FRDA）、小脑共济失调、勒伯遗传性视神经病变（LHON）、线粒体肌病、脑病、乳酸中毒、中风（MELAS）、带有红色纤维的肌阵挛性癫痫（MERFF）、肌萎缩侧索硬化症（ALS）、运动神经元疾病、亨廷顿病、黄斑变性和癫痫等疾病的治疗方法，所述方法使用本文描述的Formula I或Formula II的类胡萝卜素衍生物。
• Methods for treating diabetes
  申请人：Boddupalli Sekhar

  公开号：US20060106014A1

  公开（公告）日：2006-05-18

  Disclosed are methods for the treatment of diabetes by administering a composition comprising a pharmaceutically acceptable amount of a dual inhibitor of both 5-lipoxygenase (5-LO) and 12/15-lipoxygenase (12/15-LO) enzymes or of both 5-lipoxygenase (5-LO) and 15-lipoxygenase (15-LO) enzymes. The invention is also directed to methods of controlling blood glucose level in diabetic patients with a dual inhibitor of both 5-lipoxygenase (5-LO) and 12/15-lipoxygenase (12/15-LO) enzymes or of both 5-lipoxygenase (5-LO) and 15-lipoxygenase (15-LO) enzymes.

  本发明涉及通过给予一种含有双重抑制剂的组合物来治疗糖尿病的方法，该组合物包括一种在药学上可接受的量的5-脂氧合酶(5-LO)和12/15-脂氧合酶(12/15-LO)酶的双重抑制剂，或者包括一种在药学上可接受的量的5-脂氧合酶(5-LO)和15-脂氧合酶(15-LO)酶的双重抑制剂。本发明还涉及使用双重抑制剂的方法来控制糖尿病患者的血糖水平。
• TREATMENT OF MITOCHONDRIAL DISEASES
  申请人：Ampere Life Sciences, Inc.

  公开号：US20130267538A1

  公开（公告）日：2013-10-10

  The invention relates the method of treatment or amelioration of mitochondrial disorders such as Alzheimer's disease, Parkinson's disease, Friedreich's ataxia (FRDA), cerebellar ataxias, Leber's hereditary optic neuropathy (LHON), mitochondrial myopathy, encephalopathy, lactacidosis, stroke (MELAS), Myoclonic Epilepsy with Ragged Red Fibers (MERFF), amyotrophic lateral sclerosis (ALS), motor neuron diseases, Huntington's disease, macular degeneration, and epilepsy, with chroman derivatives of Formula I or Formula II as described herein.

  本发明涉及使用式I或式II所描述的色酮衍生物的治疗或改善线粒体疾病的方法，例如阿尔茨海默病、帕金森病、弗里德雷希共济失调症（FRDA）、小脑共济失调、勒伯遗传性视神经病变（LHON）、线粒体肌病、脑病、乳酸中毒、中风（MELAS）、带红纤维的肌阵挛性癫痫（MERFF）、肌萎缩侧索硬化症（ALS）、运动神经元疾病、亨廷顿病、黄斑退化和癫痫。
• [EN] TREATMENT OF MITOCHONDRIAL DISEASES<br/>[FR] TRAITEMENT DE MALADIES MITOCHONDRIALES
  申请人：GALILEO PHARMACEUTICALS INC

  公开号：WO2005032544A1

  公开（公告）日：2005-04-14

  The invention relates the method of treatment or amelioration of mitochondrial disorders such as Alzheimer's disease, Parkinson's disease, Friedreich's ataxia (FRDA), cerebellar ataxias, Leber's hereditary optic neuropathy (LHON), mitochondrial myopathy, encephalopathy, lactacidosis, stroke (MELAS), Myoclonic Epilepsy with Ragged Red Fibers (MERFF), amyotrophic lateral sclerosis (ALS), motor neuron diseases, Huntington's disease, macular degeneration, and epilepsy, with chroman derivatives of Formula I or Formula II as described herein.
• [EN] METHODS FOR TREATING DIABETES<br/>[FR] METHODES DE TRAITEMENT DU DIABETE
  申请人：GALILEO PHARMACEUTICALS INC

  公开号：WO2006044556A2

  公开（公告）日：2006-04-27

  [EN] Disclosed are methods for the treatment of diabetes by administering a composition comprising a pharmaceutically acceptable amount of a dual inhibitor of both 5-lipoxygenase (5-LO) and 12/15-lipoxygenase (12/15-LO) enzymes or of both 5-lipoxygenase (5-LO) and 15-lipoxygenase (15-LO) enzymes. The invention is also directed to methods of controlling blood glucose level in diabetic patients with a dual inhibitor of both 5-lipoxygenase (5-LO) and 12/15-lipoxygenase (12/15-LO) enzymes or of both 5-lipoxygenase (5-LO) and 15-lipoxygenase (15-LO) enzymes.
  [FR] Méthodes de traitement du diabète consistant à administrer une composition contenant une quantité pharmaceutiquement acceptable d'un inhibiteur double de 5-lipoxygénase (5-LO) et 12/15-lipoxygénase (12/15-LO) enzymes ou de 5-lipoxygénase (5-LO) et 15-lipoxygénase (15-LO) enzymes. Méthodes de surveillance du niveau de sucre dans le sang chez des patients diabétiques avec un double inhibiteur de 5-lipoxygénase (5-LO) et 12/15-lipoxygénase (12/15-LO) enzymes ou de 5-lipoxygénase (5-LO) et 15-lipoxygénase (15-LO) enzymes.